Examkin

Soru

Zorluk: ZorPharmacokinetic and Pharmacodynamic Principles

A 7474-year-old man with a history of nonvalvular atrial fibrillation and hypertension is admitted to the hospital with hemoptysis and a cavitary lung lesion. He is diagnosed with chronic pulmonary histoplasmosis. The infectious disease consultant recommends initiating therapy with oral itraconazole.

The patient's outpatient medications include rivaroxaban 20 mg20 \text{ mg} once daily and amlodipine 5 mg5 \text{ mg} once daily.

His baseline laboratory studies on admission show:
- Hemoglobin: 13.8 g/dL13.8 \text{ g/dL}
- Serum creatinine: 1.2 mg/dL1.2 \text{ mg/dL} (Estimated creatinine clearance: 58 mL/min58 \text{ mL/min})

Four days after starting itraconazole, the patient develops acute-onset hematemesis and melena. He becomes hypotensive and tachycardic. Repeat laboratory studies show:
- Hemoglobin: 7.4 g/dL7.4 \text{ g/dL}
- Serum creatinine: 1.4 mg/dL1.4 \text{ mg/dL}

Which of the following best describes the primary mechanism responsible for this patient's acute gastrointestinal hemorrhage?

  1. Inhibition of both cytochrome P450-mediated hepatic metabolism and P-glycoprotein-mediated active effluxCevap
  2. B
    Worsening renal function resulting in a profound decrease in the glomerular filtration of the anticoagulant
  3. C
    Initiation of an antifungal agent that is absolutely contraindicated due to the patient's concurrent use of a calcium channel blocker
  4. D
    Displacement of the anticoagulant from plasma binding proteins, leading to a transient increase in the pharmacologically active free fraction
  5. E
    Pharmacodynamic synergism at the factor Xa active site caused by the active metabolites of the antifungal agent

Cevap

The hemorrhage is caused by the inhibition of both cytochrome P450-mediated hepatic metabolism and P-glycoprotein-mediated active efflux.
The correct answer identifies the severe pharmacokinetic drug-drug interaction between direct oral anticoagulants (DOACs) and azole antifungals. Rivaroxaban's disposition depends on both cytochrome P450 3A4 (CYP3A4) for hepatic metabolism and P-glycoprotein (P-gp) for intestinal and renal efflux. Itraconazole is a potent inhibitor of both pathways. When coadministered, itraconazole prevents the metabolism and efflux of rivaroxaban, leading to a profound increase in the area under the curve (AUC) and peak plasma concentrations. This toxic accumulation directly resulted in the patient's acute, life-threatening gastrointestinal hemorrhage.

Adım Adım Çözüm

1
Identify the primary active medications involved in the clinical change.
The patient is taking rivaroxaban (a direct oral anticoagulant) and was recently started on itraconazole (an azole antifungal).
Recognizing newly added medications is critical for identifying potential drug-drug interactions that precipitate acute clinical deterioration.
2
Analyze the pharmacokinetic properties of the anticoagulant.
Rivaroxaban is metabolized hepatically by CYP3A4 and is also a substrate for the P-glycoprotein (P-gp) efflux transporter in the gut and kidneys.
Understanding the clearance pathways of direct oral anticoagulants is necessary to predict how other drugs might alter their systemic levels.
3
Determine the pharmacokinetic effect of the newly added medication.
Itraconazole is a potent inhibitor of both CYP3A4 and P-gp.
Azole antifungals, macrolide antibiotics, and protease inhibitors are classic dual inhibitors of these specific metabolic and transport pathways.
4
Synthesize the interaction to explain the patient's presentation.
The dual inhibition drastically reduces rivaroxaban clearance and increases its bioavailability, leading to supratherapeutic plasma levels and severe gastrointestinal hemorrhage.
Connecting the pharmacokinetic mechanism directly to the adverse clinical outcome confirms the diagnosis.

Anahtar Kavram

Direct oral anticoagulants like rivaroxaban and apixaban rely heavily on CYP3A4 and P-glycoprotein for clearance; concomitant administration of potent dual inhibitors (e.g., itraconazole, ritonavir) leads to dangerous drug accumulation and severe bleeding.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Pharmacokinetic and Pharmacodynamic Principles

Bu konudan daha fazla soru